Akebia Completes $22M Series B Financing

Akebia announced that it has closed a Series B financing totaling $22 million.

Akebia Therapeutics, Inc., a pharmaceutical discovery and development company, is pocketing $22 million in venture funds assigned to its second round. The money is being earmarked for work on new treatments for anemia and vascular disorders.

"This is an important financing event for Akebia because it enables us to complete two phase 2b studies for our anemia drug, AKB-6548 and will position the program for pivotal studies," said Joseph Gardner, Ph.D., the CEO of Akebia. "This financing round also enables us to advance AKB-9778, our novel Tie-2 activator for diabetic macular edema and vascular leak,

Related News

News Women in Pharma: Hiring Across the Gender Divide

In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond.

19 Oct 2023
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity

Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe...

18 Oct 2023
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests

A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test.

17 Oct 2023
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m

To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development.

16 Oct 2023
News Updated – Changing abortion pill access according to the US FDA and Supreme Court

After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug.

11 Sep 2023
News Revolutionising cancer treatment with mRNA-based therapeutics

Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours.

5 Sep 2023
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability

The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ...

28 Aug 2023
News Choosing the Right CDMO Partner: A Comprehensive Guide

Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...

28 Aug 2023

CPHI Online is the largest global marketplace in the pharma ingredients industry

Akebia Completes $22M Series B Financing

Related News

Position your company at the heart of the global Pharma industry with a CPHI Online membership

Request for general information